Exec Chat: New CEO Of Digital Therapeutics Alliance Says Reimbursement Remains Big Issue
Executive Summary
In an interview with Medtech Insight, Andy Molnar, new CEO of the Digital Therapeutics Alliance, outlines some of the big issues facing the digital therapeutics industry, which has seen tremendous growth during the pandemic.
You may also be interested in...
Big Health Digital Therapeutics Rings In 2022 With $75M Financing, FDA Alum On Board
Big Health will use its $75m in new funding to scale the business, with plans to launch six new digital therapeutics by 2024. Former US FDA official Anand Shah will join its board of directors.
Pear CEO Sees Fulfilment And Reimbursement Challenges Ahead
Medtech Insight spoke to Pear Therapeutics CEO Corey McMann about the emerging digital therapeutics market and his company’s future now that it has the first PDT covered by Medicaid.
‘Training People To Be Healthier': Digital Therapeutics Programmed For Growth
Experts foresee the digital therapeutics market growing to $6bn-$9bn by 2025, driven in part by tech-empowered consumers and patients looking for solutions to better manage their own health and conditions. For medtechs, collaborations with software-driven start-ups will be key to harnessing personalized data and differentiating themselves in the marketplace.